Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atropine + isoprenaline is a combination drug that utilizes the complementary pharmacological effects of both medications. Atropine is a selective antagonist of cholinergic receptors M1 and M2 that reverses the inhibitory effect of the vagal nerve on the myocardium, improving sinus node automatism and conduction in the atrioventricular node. Isoprenaline (also known as isoproterenol) is a non-selective beta adrenergic receptor agonist with preferential activity at beta-1 receptors, producing bathmotropic and chronotropic effects. When administered together, both drugs increase cardiac output but through different mechanisms - atropine by blocking parasympathetic effects and isoprenaline by directly stimulating beta receptors. This combination is used in the evaluation of asymptomatic sinus bradycardia and for diagnostic purposes during electrophysiological studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atropine + isoprenaline.